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Introduction
Hereditary ataxias (HAs) and hereditary spastic paraplegias (HSPs) are clinically, genetically and etiologically heterogeneous neurodegenerative disorders. HAs are characterized by a cerebellar syndrome causing progressive loss of coordination with gait and limb ataxia, accompanied by dysarthria and oculomotor signs [1] . Conversely, the main features of HSP include dysfunction of the corticospinal tract and dorsal columns, which results in spasticity and weakness in the lower limbs, in the absence of any additional neurological sign [2] . Spasticity and cerebellar ataxia are a relatively common combination, as in HSP due to SPG7 mutations, and occur in disorders that have specifically been designated as spastic ataxia [3] . In past years, several families with HSP have been described, showing cerebellar features such as ataxia, suggesting a genetic overlap between the two neurodegenerative disorders [4, 5] .
To date, more than 200 genes have been reported, encompassing recessive, dominant and X-linked HA/ HSP forms [1] (http://neuromuscular.wustl.edu/ataxia/ aindex.html). Despite this huge number of ataxias and paraplegias, more than half of all patients remain genetically undiagnosed.
Among the most interesting examples of genes involved in both HSP and HA are SPG7 and AFG3L2, encoding for the components of the mitochondrial AAA protease (m-AAA). Paraplegin and AFG3L2 have been implicated in a very broad range of neurodegenerative diseases, including pure ataxia [6] myoclonus or ataxia plus progressive myoclonic epilepsy [7, 8] , ataxia and progressive external ophthalmoplegia [9] , ataxia plus type 1 muscle fiber atrophy [10] and optic atrophy [11] [12] [13] [14] .
A recent report suggested that mutations in SPG7, causing the most common form of autosomal recessive spastic paraplegia (MIM#607259), accounted for approximately 19% of cases in a group of 70 patients with unexplained ataxia and subtle pyramidal signs in the UK [13] . All patients were homozygotes or compound heterozygotes for the c.1529C>T (p.Ala510Val) missense mutation [13] . The role of c.1529C>T as a pathogenic variant has been doubtful for many years, given its high frequency in the healthy population. This variant localizes to the C-terminal end of the protein, on the buried surface of a6 facing the a5, and a valine in this position would disturb the hydrophobic core interactions in the helical bundle, due to its greater volume [15] . Moreover, yeast complementation assays have provided evidence that the p.Ala510Val variant is not able to restore the respiratory competence of yta10Dyta12D cells and the proteolytic cleavage of the substrate protein Mrpl32, suggesting a pathogenic effect of this change [16] .
Here, we evaluated the role of p.Ala510Val change in ataxia, screening a large cohort of 895 undiagnosed unrelated patients of Italian ancestry with ataxia.
Materials and methods

Subjects
We enrolled 895 unrelated cases referred to the Genet- 
Mutation detection
We set up a rapid restriction enzyme assay for typing the c.1529C>T (p.Ala510Val) variant. Sanger sequencing was used to confirm the presence of the variant and to search for the second variant in compound heterozygotes. Details are available in Appendix S1 and Table S1 . Multiplex ligation-dependent probe amplification (MLPA) analysis for SPG7 was performed using the SALSA MLPA P213 HSP under the specified conditions (www.mlpa.com).
Results
SPG7 p.Ala510Val mutants account for 2.3% of cerebellar ataxia cases in Italy
Among the 895 patients screened using the restriction enzyme test, we identified eight homozygote and 24 heterozygote cases harboring the c.1529C>T change.
To search for a pathogenic mutation on the second allele, we sequenced the entire SPG7 coding region in all heterozygotes. We found a second variant in 13 cases (Table S2) , seven of which had already been reported as pathogenic changes (c.1A>G/p.Met1?; c.637C>T/p.Arg213*; c.773_774delTG/p.Val258Glyfs *30; c.1369C>T/p.Arg457*; c.1617delC/p.Val540Cysfs *52; c.2102A>C/p.His701Pro; c.2228T>C/p.Ile743Thr) (see references in the Supporting Information). Five genetic changes were novel: in ATA-23, we identified the c.1877T>C substitution, which changed the conserved methionine 626 into a threonine; ATA-16 and ATA-17 showed the c.1972G>A variant, causing p.Ala658Thr. These variants were predicted to be pathogenic as both affect amino acids in a highly evolutionarily conserved region of the protein (from humans to Caenorhabditis elegans), are absent from the gnomAD and 1000G databases, and are classified as pathogenic (IIIb) following American College of Medical Genetics (ACMG) guidelines (Table 1) .
In ATA-25, the c.2181G>A mutation hit the last base of exon 16, causing a synonymous amino acid change. Splicing prediction tools, however, supported an effect on canonical donor splice site. The remaining two novel variants were intronic, i.e. c.287-1G>C in ATA-14 and c.1553-2_1553-1delAG in ATA-15. Insilico prediction software showed that the c.287-1G>C substitution and the deletion c.1553-2_1553-1delAG caused the loss of the canonical acceptor site. Unfortunately, cDNA was not available to confirm splicing effects.
In the remaining 11 carriers without biallelic mutations, we excluded SPG7 single and multiple exon deletion/duplication by MLPA analysis. We also tested variants in exons 10-14-15 and 16 of the AFG3L2 (where the majority of mutations were clustered) because of the role of its protein as a partner of paraplegin in m-AAA complexes, without revealing any positive case.
Overall, 10/25 (40%, eight families) cases were p.Ala510Val homozygotes and 15/25 (60%, 13 families) cases were compound heterozygotes (Table S2 ).
In the healthy volunteers' cohort, we observed only two out of 257 individuals carrying the heterozygous c.1529C>T variant, consisting of an allelic frequency of 0.38%. No second variant was detected in the rest of the gene by direct Sanger sequencing and MLPA analysis.
Clinical features of SPG7-related ataxia cases
Clinical features of the 25 patients with SPG7 (21 families) are summarized in Table 2 and detailed  in Tables S3 and S4 . Ataxia or gait disturbances were often reported as initial symptoms. The disease started with pure dysarthria in family R, with ataxia and dysarthria in families F, Q and T, and with limb spasticity in families J, S and V.
The age at onset was 44.5 AE 8.54 years (mean AE SD). We noted a difference in age at onset between homozygotes and compound heterozygotes in the two groups [50.6 AE 7.40 vs. 40.7 AE 7.00 years (mean AE SD); P = 0.0023, Student's t-test] (Table 2) . Moreover, the SARA score at onset also revealed a difference between the two groups [6.2 AE 2.2 vs. 9.7 AE 3.6 (mean AE SD); P = 0.03, Mann-Whitney test].
This difference was maintained when comparing age at onset of our homozygous individuals with that of classical patients with SPG7 from the literature who were negative for the p.Ala510Val allele [age at onset (mean AE SD), 50.6 AE 7.40 vs. 34.8 AE 12.8 years; P = 0.0004] [12] [13] [14] [17] [18] [19] [20] [21] [22] .
Brain magnetic resonance imaging at onset presented a cerebellar hemispheric and/or vermian atrophy in 18 out of 25 patients. Cerebellar dysarthria was also manifested in 68% of patients and 32% of patients showed oculomotor signs (5/26 ophthalmoparesis, 1/26 slow saccades and 2/26 nystagmus). Pyramidal signs were present in~76% of patients, in particular hyper-reflexia (19/25) and spasticity (16/25) . About 40% of patients showed a defect in proprioceptive sensation. Only three patients presented with urinary urgency at onset.
On follow-up examination (mean 12.5 years of disease duration), 20/23 patients showed hyper-reflexia and 18/23 showed spasticity. Magnetic resonance imaging studies identified a marked hemispheric and vermian atrophy of the cerebellum in ATA-12 and ATA-25. Nystagmus initially reported in patients ATA-3 and ATA-13 progressed to ophthalmoparesis. A total of 10 out of 23 patients showed urinary urgency. SARA scores became more similar between the two groups; however, values rating stance at follow-up maintained a difference (mean AE SD, 1.44 AE 1.0 vs. 2.67 AE 1.5; P = 0.012, Mann-Whitney test).
Discussion
The huge genetic heterogeneity of HA and HSP is accompanied by allelic heterogeneity, given that the same gene can be associated with HA, HSP or mixed phenotypes. One such example is given by SPG7. Indeed, whereas SPG7 complete loss of function seems to be associated with HSP type 7, likely hypomorphic variants, such as p.Ala510Val, have been repeatedly described in HA.
To further study the role of p.Ala510Val, we collected and screened 895 Italian cases from different Only the first author of each study is given. AAA, ATPases associated with diverse cellular activities domain; ExAC, exome aggregation consortium; NMD, nonsense mediated decay; PhD-SNPg, predicting human deleterious SNPs in human genome; PON-P, PMUT, pathogenic-or-not-pipeline; SIFT, sorting intollerant from tolerant.
regions using a rapid genetic test developed in-house. This survey represents the largest group of patients with ataxia so far analyzed for this variant. We identified 25 cases from 21 families (2.3%) who were homozygous or compound heterozygous for p.Ala510Val and another pathogenic variant in SPG7.
These patients presented with an ataxic phenotype at onset, explaining why SPG7 was not considered for the initial screening. As expected, the majority of cases were negative for familial history; only four autosomal recessive cases (A, F, Q and R) were reported.
Overall, the frequency of SPG7-related cerebellar ataxias in our cohort was lower when compared with previously reported surveys from other populations, ranging from 18.6% in British patients to 19.3% in French-Canadian cases [13, 19] . This frequency may indicate a lower prevalence of the variant in patients of Italian ancestry with SPG7. Indeed, in our control cohort of 257 healthy individuals of Italian origin, we only identified two p.Ala510Val alleles (0.4%), corroborating the results obtained by Arnoldi et al. [23] in their analysis of HSP cases in Italian families.
Although a precise estimate of age at onset is difficult in HA and HSP, we confirm the variable age of onset [mean AE SD, 44.5 AE 8.54 (range 29-63) years], which was always in adulthood. We noted a difference when comparing the age at onset of homozygote and compound heterozygote individuals, with the former developing the disease approximately 10 years later than the latter (P = 0.002). This difference is maintained when comparing age at onset of our homozygous individuals with that of classical patients with SPG7 from the literature who were negative for the p.Ala510Val allele [age at onset (mean AE SD), 50.6 AE 7.40 vs. 34.8 AE 12.8 years; P = 0.0004] [12] [13] [14] [17] [18] [19] [20] [21] [22] . Although interesting, these differences need further confirmation in larger surveys.
Using the SARA, we showed that p.Ala510Val homozygotes have a milder phenotype at onset versus compound heterozygotes (P = 0.03). At follow-up (disease duration, 13.7 years in homozygotes vs. 11.7 years in compound heterozygotes), homozygotes and compound heterozygotes are indistinguishable except for stance. Indeed, the majority of compound heterozygotic patients are no longer able to stand with feet together without sway, whereas homozygotic patients have lost only the ability to stand in tandem. These results are in agreement with the less severe effect of p.Ala510Val compared with other variants and may help to explain why this allele is so frequent in several populations. Thus, SPG7 complete loss of function seems to be associated with a more severe phenotype, whereas a partially residual function seems to be associated with a milder phenotype. Given its mild effect, it is possible that other genes play a role in cases with p.Ala510Val. Among these, AFG3L2 is the most likely candidate, as its protein is a component of the m-AAA heterohexamer with paraplegin. Thus, we may speculate that, in cases with p.Ala510Val, the phenotype is modulated by variants acting on SPG7/AFG3L2 expression or on AFG3L2 itself. A role for AFG3L2 as modifier has already been proven by our group in a family with ataxia with oculomotor apraxia type 2 [7] .
In addition to p.Ala510Val, we also found 13 other variants in the compound heterozygous state.
In ATA-13, we identified c.2102A>C, causing the change of a highly conserved histidine in position 701 to a proline, within the catalytic metallopeptidase domain of paraplegin. This mutation had previously been described only in Norwegian families, residing on a founder haplotype [24] .
In ATA-24, we found the truncating mutation c.637C>T, p.Arg213*, already reported in a sporadic case of amyotrophic lateral sclerosis. As suggested by the authors, this is not surprising given that amyotrophic lateral sclerosis and SPG7 share common clinical features and might therefore represent a differential diagnosis [25] .
We also reported five novel SPG7 mutations as pathogenic: two missense (p.Met626Thr, p.Ala658Thr), a single synonymous amino acid change (p.Ala727Ala), which probably affects the canonical donor splice site, and two intronic variants affecting the canonical acceptor splice site (c.287-1 G>C, c.1553-2_1553-1delAG) falling in the IIIb group.
In 11 patients, the second variant could not be detected, probably because our SPG7 testing had limitations. We excluded point mutations in coding regions and exon boundaries (AE50 bp), and intragenic deletion/duplication. Regulatory variants or deep intronic changes affecting splicing were not searched for in our study and therefore the analysis of these regions could be a promising approach in the identification of unreported but pathogenic variants.
Moreover, driven by the participation in m-AAA complexes, we hypothesized a role for AFG3L2 as a phenotype modifier. Unfortunately, no variants were found, confirming data obtained by Klebe et al. [12] .
In conclusion, we confirmed that cerebellar ataxia can be the main clinical symptom at onset in HSP type 7 and therefore SPG7 should be considered in the differential diagnosis of sporadic and recessive late-onset ataxias, also in the Italian population. Given the frequency of the c.1529C>T allele, where access to reasonably cheap panels is not available, one could consider doing a tiered approach in sporadic/recessive ataxias and testing this variant after the exclusion of Friedreich ataxia and the most common spinocerebellar ataxias.
Moreover, genotype appears to predict onset of clinical manifestations and disease progression, further elements that are worthy of consideration when counseling patients.
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